Navigation Links
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Date:8/29/2010

to placebo or teriflunomide, 7mg or 14mg, once daily. The primary endpoint was annualized relapse rate defined as the number of confirmed relapses per patients-year. The key secondary endpoint was the time to disability progression measured by EDSS. Safety and tolerability evaluations were based on treatment emergent adverse events, physical examinations, vital signs and laboratory investigations.

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, unpredictable and progressively disabling disease. Patients with MS typically are diagnosed at a young age and they face a lifetime of uncertainty with gradually declining health. Today, over two million people around the world suffer from MS. MS is the result of damage to myelin, a protective sheath surrounding nerve fibres of the central nervous system. When myelin is damaged, this interferes with messages between the brain and other parts of the body. Multiple sclerosis is a very variable condition and the symptoms depend on which areas of the central nervous system have been affected. There is no definite pattern to MS and everyone with MS has a different set of symptoms, which vary from time to time and can change in severity and duration, even in the same person. Management of MS is complex; early intervention in the pathological process is recommended in order to delay disease progression or at least, slow it down. A complex support system is required for the care of MS patients, including health and social services, as well as various healthcare professionals. Although there is no known cure for multiple sclerosis, several therapies are proven to be helpful but there remains an unmet need for new oral therapies with an acceptable benefit/risk profile.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
3. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
4. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
5. Study Shows Machine Perfusion Significantly Improves Transplant Results
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
8. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
9. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
11. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... PMG Research, Inc. announced today the formation of ... sites that provide clinical research services to pharmaceutical companies and ... its partnerships with large physician practices and integrated health systems. ... the Southeastern United States and spans over 60 physician practices. ... will be held by: Dr. Robert Holmes, MD, of PMG ...
(Date:11/26/2014)... The Pittcon marketing department is pleased to ... mobile app, Pittcon 2015 . ... Store for iOS and Android devices and the Kindle ... and after the event. It acts as an all-inclusive ... sessions, Conferee Networking sessions and short courses. , The ...
(Date:11/26/2014)... Texas (PRWEB) November 26, 2014 ... Industry is an in-depth research report on the ... the report introduces Palmitic Acid, basic information, including ... policy analysis, and news analysis, etc. , ... analyzes Palmitic Acid market in China ...
(Date:11/24/2014)... , Nov. 24, 2014  IGI Laboratories, Inc. ... based specialty generic pharmaceutical company, today announced it ... to the U.S. Food and Drug Administration (FDA), which ... 2014 to seven, with eighteen submissions now pending at ... President and CEO of the Company, commented, "Our team ...
Breaking Biology Technology:PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3Pittcon Releases 2015 Mobile App 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3IGI Laboratories, Inc. Announces ANDA Submission 2
... VisEn Medical Inc., a leader in fluorescence in vivo ... of its new Cat-K FAST (TM) ... with disease progression and therapeutic response in vivo . ... therapeutic target in a range of bone-related diseases, including cancer metastasis ...
... 7 Mylan Inc. (Nasdaq: MYL ) today ... from the U.S. Food and Drug Administration (FDA) for its ... , , Bicalutamide Tablets are the generic version of ... of approximately $322 million for the 12 months ending March ...
... MATEO, Calif., July 7 King Pharmaceuticals, Inc. (NYSE: ... today announced that on July 2, 2009, King met with the ... Letter regarding the New Drug Application (NDA) for REMOXY(R). The ... to resubmit the REMOXY(R) NDA and to address all FDA comments ...
Cached Biology Technology:VisEn Launches New Cat-K FAST(TM) Fluorescence Molecular Imaging Agent 2King and Pain Therapeutics Announce REMOXY(R) NDA Update 2King and Pain Therapeutics Announce REMOXY(R) NDA Update 3
(Date:11/4/2014)... right amount of death at the right time might ... new research that could help in understanding animal populations, ... In a paper in the journal Trends in ... European colleagues conclude that the kind of positive population ... individuals, or mortality, depends on the size and developmental ...
(Date:11/4/2014)... , November 4, 2014   ... vertical market growth   Fuel3D , a ... closed a funding round totaling $6.4 million (£4 million). This ... funding secured earlier this year and paves the way for ... 2015. The funding round was led by Chimera ...
(Date:11/3/2014)... Center study published in this month,s ... the activity of a recently discovered communication molecule of ... has been known to limit inflammation and the current ... IL-37 inhibits the ability of the immune system to ... that underlies IL-37,s effect on the immune system now ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... In the past it could take several hours for ... be treated with for a particular infection. Using a ... with the Danish biotech research company Unisensor A/S, Aalborg ... period has been more than halved. The significantly shorter ...
... The story of why we are all so different ... through breeding. A new study in the journal Nature ... individual variation found in fruit flies that uses components operating ... new mechanism is based in a surprising genetic oddity. Nearly ...
... , DALLAS Nov. 7, 2013 UT Southwestern ... of mice increased their susceptibility to inflammatory disease, indicating ... controlled by the body,s circadian clock. The study ... identifies a previously hidden pathway by which the ...
Cached Biology News:Battle against resistant bacteria takes huge leap forward 2Edited RNA + invasive DNA add individuality 2Edited RNA + invasive DNA add individuality 3UT Southwestern researchers identify how body clock affects inflammation 2UT Southwestern researchers identify how body clock affects inflammation 3
MAb to HLA, Class II-DR+DP Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
... Corning CellBIND surface is produced by a ... hydrophilic surface giving more consistent, even cell ... enhances cell attachment and growth uunder difficult ... • CellBIND may provide a more ecominic ...
... suspension array system, 100-240 V, uses multiplex ... quantitative analysis of up to 100 proteins ... The suspension array is composed of up ... which may be conjugated with a unique ...
... PYREX Delong style shaker flasks have three ... agitation of solutions to improve oxygen or ... reciprocating shakers. The long neck reduces splashing ... Their uniform wall thickness provides the proper ...
Biology Products: